

Amendments to the Claims


This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A method to normalize the contractile response of ~~an endothelial~~  
~~compromised vascular smooth muscle cell in response to a vasoconstrictor agonist~~  
~~vasculature~~ in a patient in need of such normalization, the vasculature comprising a vascular  
smooth muscle cell layer and a compromised endothelial cell layer, wherein the method  
comprising comprises administering a pharmaceutically effective amount of a CLC3 blocker,  
or a pharmaceutically acceptable salt thereof.
- 2-5. (Cancelled)
6. (Previously Presented) A method of claim 23, wherein the compound administered is 1-p- $\beta$ -  
dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable  
salt thereof.
7. (Previously presented) A method of claim 23, wherein the patient has diabetes.
8. (Previously presented) A method of claim 23, wherein the patient has had a surgical  
procedure.
9. (Previously presented) A method of claim 23, wherein the patient has hypertension.
10. (Previously presented) A method of claim 23, wherein the patient has coronary artery  
disease.
11. (Previously presented) A method of claim 23, which further comprises administering a  
pharmaceutically-effective compound selected from the group consisting of: an anti-diabetes  
agent; an anti-hypertension agent; an anti-coronary artery disease agent; and an anti-  
restenosis agent.

12-22. (Cancelled)

23. (Previously presented) A method of claim 1, wherein the CLC3 blocker is a compound of Formula I



wherein

either R<sup>4</sup> is H or a lower alkyl radical and R<sup>5</sup> is a lower alkyl radical, or R<sup>4</sup> and R<sup>5</sup> are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

R<sup>6</sup> is H or a lower alkyl radical;

R<sup>7</sup> is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

R<sup>8</sup> is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

24. (Cancelled)

25. (Currently Amended) A method to normalize the contractile response of an endothelially compromised vascular smooth muscle cell vasculature in response to a vasoconstrictor agonist in a patient in need of such normalization, the vasculature comprising a vascular smooth muscle cell layer and a compromised endothelial cell layer, wherein the method

comprising comprises administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof, and wherein the vasoconstrictor agonist is norepinephrine, KCl or serotonin.